RAGE (receptor for advanced glycation end-products)

Class

Inhaled RNAi therapeutic silencing RAGE expression in pulmonary epithelium

RAGE, the receptor for advanced glycation end-products, is a cell-surface receptor that recognizes a broad set of danger-associated molecules, including modified sugars called advanced glycation end-products, the alarmin protein HMGB1, and certain S100 calcium-binding proteins. Engagement of RAGE by these ligands activates intracellular signaling that promotes inflammation and oxidative stress. In the lung, RAGE is expressed at particularly high levels on alveolar epithelial cells, where sustained activation has been linked to chronic inflammatory and fibrotic disease processes, including conditions such as pulmonary fibrosis and chronic obstructive airway disease. The biological rationale for silencing RAGE is that reducing receptor abundance should dampen this inflammatory signaling cascade before it amplifies tissue damage. An inhaled RNA interference (RNAi) approach delivers small interfering RNA directly to pulmonary epithelial cells, degrading RAGE messenger RNA and lowering receptor protein levels locally, in principle limiting systemic exposure and off-target silencing elsewhere in the body. This organ-targeted route reflects a broader trend of using RNAi to address disease mechanisms confined largely to a single tissue, exploiting the accessibility of the lung epithelium to inhaled formulations rather than relying on systemic small-molecule or antibody blockade.